Tag:
QLT
Latest Headlines
Latest Headlines
Fierce's 5 Drug Delivery Companies to Watch
This year we're naming Fierce 's 5 Drug Delivery Companies to Watch. All are making their mark by bringing drug delivery technology into everyday medical device and pharmaceutical use.
QLT's delivery plugs face issues, analyst says
Tear duct plugs to deliver eye drugs face some challenges, such as keeping the tiny devices in place to release treatments. QLT ( $QLTI ), the Canadian eye drug specialist, has been on pushing ahead
QLT reports success with eye drug delivery, analyst skeptical
Vancouver-based QLT ( $QLTI ), a developer of plugs inserted at the opening of the tear ducts to deliver eye treatments, is reporting that its Latanoporst punctal plug delivery system is certainly
QLT sells U.S. unit for $230M
Canada's QLT has sold its subsidiary QLT USA to Tolmar Holdings, a Colorado-based private pharma company, for $230 million. QLT USA's lead asset is Eligard, a line of products for prostate cancer. A
QLT stock rockets as acne drug is cleared for takeoff
Shares of QLT rocketed up 55 percent in a tense market yesterday after the biotech finished a lengthy task in persuading the FDA that a blood test should not be required before doctors prescribe its
ALSO NOTED: Nuvelo drug gets fast tracked; QLT brings on Goldman Sachs; and much more...
> Sanofi-Aventis has set up a small executive committee to set strategy, allocate resources and oversee company management, according to anonymous sources who talked to APM Europe. The idea is to
QLT posts 'for sale' sign
The board at Canada's QLT has decided to put itself up for sale after concluding that its business plan won't work. The announcement comes after sales of Visudyne, an eye therapy developed by QLTs,
QLT gains drug delivery tech in $42M buyout
Canada's QLT has snapped up new drug delivery technology for eye conditions with its $42 million acquisition of ForSight Newco II. The deal also includes $40 million in scheduled milestones for the
Canadian biotech stocks suffer as bad news mounts
Canada's National Post chronicles some tough times in the country's biotech sector. Former high-flyers like QLT and Angiotech have seen their stocks
QLT delays clinical program on Atrigel
Canada's QLT has opted to delay a human trial of an experimental therapy, Atrigel, for people with hormone disorders after reporting adverse events in a primate study. The FDA wants to review data on the primate study before the clinical program gets underway. QLT says it should be able to submit the data by the end of the year. Atrigel is being developed for people whose pituitary glands produce excess growth hormones.
- here's the AP report for more information
